These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 8759604)

  • 1. Gene expression of DNA topoisomerases I, II alpha and II beta and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.
    Cornarotti M; Capranico G; Bohm S; Oriana S; Spatti GB; Mariani L; Ballabio G; Zunino F
    Int J Cancer; 1996 Aug; 67(4):479-84. PubMed ID: 8759604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative and qualitative aspects of topoisomerase I and II alpha and beta in untreated and platinum/cyclophosphamide treated malignant ovarian tumors.
    van der Zee AG; de Jong S; Keith WN; Hollema H; Boonstra H; de Vries EG
    Cancer Res; 1994 Feb; 54(3):749-55. PubMed ID: 8306337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung.
    Giaccone G; van Ark-Otte J; Scagliotti G; Capranico G; van der Valk P; Rubio G; Dalesio O; Lopez R; Zunino F; Walboomers J
    Biochim Biophys Acta; 1995 Dec; 1264(3):337-46. PubMed ID: 8547322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topoisomerase II alpha expression in squamous cell carcinomas of the head and neck.
    Stathopoulos GP; Kapranos N; Manolopoulos L; Papadimitriou C; Adamopoulos G
    Anticancer Res; 2000; 20(1A):177-82. PubMed ID: 10769652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer.
    Codegoni AM; Broggini M; Pitelli MR; Pantarotto M; Torri V; Mangioni C; D'Incalci M
    Gynecol Oncol; 1997 Apr; 65(1):130-7. PubMed ID: 9103402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy.
    van der Zee AG; Hollema H; de Jong S; Boonstra H; Gouw A; Willemse PH; Zijlstra JG; de Vries EG
    Cancer Res; 1991 Nov; 51(21):5915-20. PubMed ID: 1682037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer.
    Hengstler JG; Lange J; Kett A; Dornhöfer N; Meinert R; Arand M; Knapstein PG; Becker R; Oesch F; Tanner B
    Cancer Res; 1999 Jul; 59(13):3206-14. PubMed ID: 10397267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between Topo II alpha expression and chemosensitivity testing for Topo II-targeting drugs in gynaecological carcinomas.
    Koshiyama M; Fujii H; Kinezaki M; Yoshida M
    Anticancer Res; 2001; 21(2A):905-10. PubMed ID: 11396183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic diagnosis for chemosensitivity with drug-resistance genes in epithelial ovarian cancer.
    Naniwa J; Kigawa J; Kanamori Y; Itamochi H; Oishi T; Shimada M; Shimogai R; Kawaguchi W; Sato S; Terakawa N
    Int J Gynecol Cancer; 2007; 17(1):76-82. PubMed ID: 17291235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line.
    Harker WG; Slade DL; Parr RL; Feldhoff PW; Sullivan DM; Holguin MH
    Cancer Res; 1995 Apr; 55(8):1707-16. PubMed ID: 7712479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients.
    Chen YJ; Yuan CC; Chow KC; Wang PH; Lai CR; Yen MS; Wang LS
    Gynecol Oncol; 2005 Apr; 97(1):110-7. PubMed ID: 15790446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and characterization of five cell models for chemoresistance studies of human ovarian carcinoma.
    Li L; Luan Y; Wang G; Tang B; Li D; Zhang W; Li X; Zhao J; Ding H; Reed E; Li QQ
    Int J Mol Med; 2004 Aug; 14(2):257-64. PubMed ID: 15254775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of DNA topoisomerase I and DNA topoisomerase II-alpha in carcinoma of the colon.
    Staley BE; Samowitz WS; Bronstein IB; Holden JA
    Mod Pathol; 1999 Apr; 12(4):356-61. PubMed ID: 10229499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas.
    Koshiyama M; Fujii H; Kinezaki M; Morita Y; Nanno H; Yoshida M
    Anticancer Res; 2001; 21(4B):2925-32. PubMed ID: 11712788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Expression of topoisomerase III alpha in epithelial ovarian tumors of different types and relation between the expression of topoisomerase III alpha and the clinical pathology of tumor].
    Zhang WY; Pan Y; Zhu LR; Zhang JZ; Zhang M; Feng K; Zhou L; Yu L; Zhang XM; Ng SW
    Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(42):2988-91. PubMed ID: 16324386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Higher expression of topoisomerase II in lung cancers than normal lung tissues: different expression pattern from topoisomerase I.
    Hasegawa T; Isobe K; Nakashima I; Shimokata K
    Biochem Biophys Res Commun; 1993 Aug; 195(1):409-14. PubMed ID: 8395833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression and relationship between topoisomerase I and II alpha genes in tumor and normal tissues in esophageal, gastric and colon cancers.
    Kim R; Ohi Y; Inoue H; Toge T
    Anticancer Res; 1999; 19(6B):5393-8. PubMed ID: 10697567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical and two-parameter flow cytometric studies of DNA topoisomerase II alpha in human epithelial ovarian carcinoma and germ cell tumor.
    Tanoguchi K; Sasano H; Yabuki N; Kikuchi A; Ito K; Sato S; Yajima A
    Mod Pathol; 1998 Feb; 11(2):186-93. PubMed ID: 9504690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.
    Righetti SC; Della Torre G; Pilotti S; Ménard S; Ottone F; Colnaghi MI; Pierotti MA; Lavarino C; Cornarotti M; Oriana S; Böhm S; Bresciani GL; Spatti G; Zunino F
    Cancer Res; 1996 Feb; 56(4):689-93. PubMed ID: 8630996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The association between the p53/topoisomerase I and p53/ topoisomerase IIalpha immunophenotypes and the progression of ovarian carcinomas.
    Bar JK; Grelewski P; Noga L; Rabczyński J; Gryboś M; Jeleń M
    Adv Clin Exp Med; 2012; 21(1):35-42. PubMed ID: 23214297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.